Comparison of conditioning regimens for autologous stem cell transplantation in children with acute myeloid leukemia: A nationwide retrospective study in Japan. Issue 1 (30th September 2018)

• Record Type: Journal Article
• Authors: Sakaguchi, Hirotoshi; Muramatsu, Hideki; Hasegawa, Daiichiro; Kudo, Kazuko; Ishida, Hiroyuki; Yoshida, Nao; Koh, Katsuyoshi; Noguchi, Maiko; Shiba, Norio; Tokimasa, Sadao; Fukuda, Takhiro; Goto, Hiroaki; Miyamura, Takako; Nakazawa, Yozo; Hashii, Yoshiko; Inoue, Masami; Atsuta, Yoshiko
• Is Part Of: Pediatric blood & cancer. Volume 66:Issue 1(2019)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2018-09-30
• Subjects: acute myeloid leukemia -- autologous bone marrow transplantation -- autologous peripheral blood stem cell transplantation -- myeloablative conditioning regimen; Tumors in children -- Periodicals; Blood -- Diseases -- Periodicals; Cancer in children -- Periodicals; 618.92
• DOI: 10.1002/pbc.27459
• Languages: English
• ISSNs: 1545-5009

Abstract

Abstract: Background: Indications for hematopoietic stem cell transplantation (HSCT) have decreased with the improvement in chemotherapy for pediatric acute myeloid leukemia (AML) in the last decade. We conducted reevaluation of autologous HSCT (AHSCT) to compare myeloablative conditioning (MAC) regimens for pediatric AML without the need for consideration of toxicities caused by allogeneic immune reactions. Procedure: This retrospective study analyzed the clinical outcomes of 220 children with AML who underwent consecutive AHSCT between 1989 and 2002 in Japan by the national prospective registry. The transplantation outcomes of various conditioning regimens were compared. Results: The median follow‐up period of the survivors was 160 months. The clinical outcomes of busulfan + cyclophosphamide ± etoposide or busulfan + melphalan regimens were significantly superior compared with other busulfan‐based and total body irradiation‐based regimens (leukemia‐free survival [LFS]: 68% vs 42% and 55%, P = 0.001; overall survival [OS]: 74% vs 49% and 61%, P < 0.001). Multivariate analysis showed that busulfan + cyclophosphamide ± etoposide and busulfan + melphalan regimens were independent favorable factors for LFS (hazard ratio: 0.46; P < 0.001) and OS (hazard ratio: 0.40; P < 0.001) compared with the other busulfan‐based regimen, and both age 2 years or older and advanced stage at AHSCT were independent poor predictors for LFS and OS, simultaneously. Conclusion: Busulfan + cyclophosphamide ± etoposide and busulfan + melphalan regimens exhibited superior antileukemic effects compared with other BU‐based myeloablative regimens.